Femasys Inc. (FEMY)
| Market Cap | 31.09M |
| Revenue (ttm) | 1.63M |
| Net Income (ttm) | -18.82M |
| Shares Out | 27.15M |
| EPS (ttm) | -0.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 171,697 |
| Open | 1.130 |
| Previous Close | 1.140 |
| Day's Range | 1.105 - 1.130 |
| 52-Week Range | 0.860 - 1.800 |
| Beta | -2.55 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+904.37%) |
| Earnings Date | May 8, 2025 |
About FEMY
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. Its product candidate, FemBloc, is a no... [Read more]
Financial Performance
In 2024, Femasys's revenue was $1.63 million, an increase of 51.97% compared to the previous year's $1.07 million. Losses were -$18.82 million, 32.1% more than in 2023.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for FEMY stock is "Strong Buy." The 12-month stock price forecast is $11.5, which is an increase of 904.37% from the latest price.
News
Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update
-- Company expands commercial product offering with FemBloc ® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 ...
Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations
Femasys continues to expand access and market share for its first-line infertility treatment option Femasys continues to expand access and market share for its first-line infertility treatment option
Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain
-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® -- ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) --...
Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach
First-in-world approval of FemBloc delivery system for women seeking permanent birth control First-in-world approval of FemBloc delivery system for women seeking permanent birth control
Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials
--Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners-- ATLANTA, Feb. 25, 2025 (GLOB...
Femasys Announces UK Regulatory Approvals for FemaSeed® for Female Infertility Treatment and Two Diagnostic Devices
ATLANTA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disrup...
Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception European patents expand coverage for both esse...
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment
FemaSeed® patent application provides additional coverage for Femasys' therapeutic option for women seeking infertility solution
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment
Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients Trial results demonstrated safety and effect...
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update
Company accelerated commercialization with significant new partnerships both in the U.S. and Europe Company accelerated commercialization with significant new partnerships both in the U.S. and Europe
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control
FemBloc issued patent provides additional coverage for Femasys' therapeutic option for women seeking permanent birth control FemBloc issued patent provides additional coverage for Femasys' therapeutic...
Femasys to Exhibit at ASRM 2024 and Participate in the Congress' KEEPR Education Program
Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council Company's VP of Education and Global Training Named Chairman of ASRM Corporate Member Council
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments
ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-off...
Femasys Announces Infertility Clinic Customers from Coast to Coast
Leading medical clinics become key regional resources to offer FemaSeed infertility treatment Leading medical clinics become key regional resources to offer FemaSeed infertility treatment
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market
Company taps Comercial Medico Quirurigca, SA and Durgalab as first EU distributors for its CE-marked women's reproductive healthcare products Company taps Comercial Medico Quirurigca, SA and Durgalab ...
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currentl...
Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting
ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-of...
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-of...
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-offic...
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
The Congresswoman representing Georgia's 7th district in the U.S. House of Representatives toured Femasys' facilities to gain a better understanding of our advancements for women's reproductive health...
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
Company gained CE Mark approval for four of its women's health products and completed buildout of commercial team for its infertility portfolio Company gained CE Mark approval for four of its women's ...
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
Leading women's reproductive health conference directly follows the company's EU CE Mark approval for four of its products Leading women's reproductive health conference directly follows the company's...
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
Lee-Sepsick Discussed Company's FemCerv® Endocervical Tissue Sampler and its Role in Cervical Cancer Diagnosis Lee-Sepsick Discussed Company's FemCerv® Endocervical Tissue Sampler and its Role in Cerv...
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council
Lee-Sepsick Discussed Atlanta-Based Biomedical Company's Women's Reproductive Health Products Lee-Sepsick Discussed Atlanta-Based Biomedical Company's Women's Reproductive Health Products
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
-- Recruitment of the commercial team for our infertility portfolio and the pivotal trial of FemBloc ® for permanent non-surgical birth control continues -- ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- F...